← Leaderboards
Fang Fang
Perlan Therapeutics, Inc.
$2,943,575
Attributed
$2,943,575
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $887.5K · FY2005–10$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$2,943,575 · 6
By mechanism
R43$2,350,443 · 5
R44$593,132 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Disease /Disorder Prevention /Control”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$69,532,406
- John C S Breitner · Johns Hopkins University$33,065,187
- Bruce J Hillman · American College Of Radiology$31,033,703
- Sarah E. Fowler · George Washington University$23,658,382
- Robert W Hobson · Univ Of Med/Dent Of Nj-Nj Medical School$20,632,366
- Mary M Horowitz · Medical College Of Wisconsin$20,197,116
Research focus
Disease /Disorder Prevention /ControlProtein EngineeringDrug Screening /EvaluationCommon ColdImmunologic Substance Development /PreparationDrug Design /Synthesis /ProductionAntiviral AgentsCell Adhesion MoleculesInfluenzaPeptide LibraryRhinovirusProtease InhibitorBiotherapeutic AgentRespiratory VirusProtein PurificationSerine ProteinasesMonoclonal AntibodyEscherichia ColiImmunopharmacologyDrug Quality /StandardDrug Discovery /IsolationEnzyme Linked Immunosorbent AssayPolymerase Chain ReactionTissue /Cell Culture
Grant awards (8)
Proof-of-Principle Studies of DAS181 for Parainfluenza Virus Infection$299,998
R43 · FY2010 · AI · contact PI
A Novel Therapeutics for Pandemic &Epidemic Flu$500,000
R43 · FY2005 · AI
Identifying Broad-Spectrum Influenza Virus Inhibitors$387,459
R43 · FY2005 · AI
Novel Therapeutics for Pandemic and Epidemic Flu$500,000
R43 · FY2004 · AI
Identifying Broad-Spectrum Influenza Virus Inhibitors$449,902
R43 · FY2004 · AI
Development of ColdSol TMfor Rhinovirus Infections$593,132
R44 · FY2002 · AI
Tetravalent Humanized Anti-ICAM for Rhinovirus Infection$106,542
R43 · FY2001 · AI
Affinity Enhancement of a Humanized Anti-ICAM Antibody$106,542
R43 · FY2001 · AI